SITM

Sitime Corp Information Technology Semiconductors & Related Devices Russell 3000
$447.06Close $11.8BMarket cap $252.76 – $901.4852-week range Nov 4, 2026Next report · after the close

Highlights

Cautions

  • Not in an uptrend 3 of 8 trend conditions
  • Far from its high 50% below its 52-week high
  • Results soon Nov 4, 2026, in 3 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 6, 2026
Off 12-month high 50%
1wk down 2.9% price change
1mo down 31.4% price change
12-month return up 61% market up 11% · its own up 50%
F-score 7 / 9 Strong
Altman Z 51.57 Low risk
P/E — price / earnings
PEG — P/E / EPS growth
P/B 10.2× price / book
Earnings yield down 0.6% EBIT / enterprise value
Cheaper than 21% of the market · expensive
Revenue growth up 61% year on year
EPS growth — latest quarter
Sales growth up 127% latest quarter · +38 pts
ROE down 5% return on equity
Free cash margin up 11% $35.1M FCF
D/E — long-term debt / equity
Net debt / EBITDA —
Interest cover —EBIT / interest
Piotroski tests
  • not yet profitable on its assets
  • issued more shares
  • generating cash from operations
  • profitability improving
  • profits backed by cash
  • reduced long-term debt
  • short-term liquidity improved
  • gross margin widened
  • assets working harder

Repair signals

  • FCF turned positive ($-13M → $35M)
  • Gross margin 51.6% → 53.6%

Trade setup

ATR% 8.4% $37.36 a day · 2×ATR $372.34
RS 54 / 99 vs the universe
Trend 3 / 8 trend template
Relative volume 1.5× vs 50-day average
Up/down volume 1.11 50 sessions
Implied move — no option chain · report Nov 4, 2026
Trend template · 3 of 8
  • Price above the 150 and 200-day averages: fails
  • 150-day average above the 200-day: passes
  • 200-day average rising for a month: passes
  • 50-day average above the 150 and 200-day: fails
  • Price above the 50-day average: fails
  • At least 30% above the 52-week low: passes
  • Within 25% of the 52-week high: fails
  • RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged
  • Shareholders diluted The share count rose 11.4% over the year, from 24m to 26m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported Aug 5, 2026
Results reaction Aug 5, 2026+18% vs market2 sessions after results

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $326.7M +61% on FY2024
$0 $500M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $116.2M FY2021 · $218.8M FY2022 · $283.6M FY2023 · $144.0M FY2024 · $202.7M FY2025 · $326.7M
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$42.9M
-$100M $0 $50M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · -$9.4M FY2021 · $32.3M FY2022 · $23.3M FY2023 · -$80.5M FY2024 · -$93.6M FY2025 · -$42.9M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $35.1M back to a profit
-$20M $0 $50M FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $10.5M FY2021 · $28.2M FY2022 · $8.0M FY2023 · -$889,000 FY2024 · -$13.0M FY2025 · $35.1M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 54%
  • Net -13%
  • Free cash 11%
-100% 0% 100% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Gross 50% · Net -8% · Free cash 9% FY2021 · Gross 64% · Net 15% · Free cash 13% FY2022 · Gross 65% · Net 8% · Free cash 3% FY2023 · Gross 57% · Net -56% · Free cash -1% FY2024 · Gross 52% · Net -46% · Free cash -6% FY2025 · Gross 54% · Net -13% · Free cash 11%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology
  • Cash
  • Long-term debt
$0 $1B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $73.5M FY2021 · Cash $559.5M FY2022 · Cash $34.6M FY2023 · Cash $9.5M FY2024 · Cash $6.1M FY2025 · Cash $16.8M
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 26.30m +53.3% since FY2020
26.30m 17.15m FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 17.15m FY2021 · 20.82m FY2022 · 21.70m FY2023 · 22.69m FY2024 · 23.60m FY2025 · 26.30m
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $116.2M $218.8M $283.6M $144.0M $202.7M $326.7M
Gross margin 50% 64% 65% 57% 52% 54%
Operating income -$8.6M $32.8M $16.1M -$107.2M -$115.2M -$67.0M
Net income -$9.4M $32.3M $23.3M -$80.5M -$93.6M -$42.9M
Net margin -8% 15% 8% -56% -46% -13%
Earnings per share -$0.58 $1.53 $1.03 -$3.63 -$4.05 -$1.72
Free cash flow $10.5M $28.2M $8.0M -$889,000 -$13.0M $35.1M
Free cash margin 9% 13% 3% -1% -6% 11%
Cash $73.5M $559.5M $34.6M $9.5M $6.1M $16.8M
Shareholders' equity $109.9M $632.5M $708.5M $708.1M $699.7M $1.2B
Shares outstanding 17.15m 20.82m 21.70m 22.69m 23.60m 26.30m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Aug 6, 2026 Quarterly ↗ Jun 30, 2026 37d
May 7, 2026 Quarterly ↗ Mar 31, 2026 37d
Feb 11, 2026 Annual ↗ Dec 31, 2025 42d
Nov 6, 2025 Quarterly ↗ Sep 30, 2025 37d
Aug 7, 2025 Quarterly ↗ Jun 30, 2025 38d
May 8, 2025 Quarterly ↗ Mar 31, 2025 38d
Feb 14, 2025 Annual ↗ Dec 31, 2024 45d
Nov 7, 2024 Quarterly ↗ Sep 30, 2024 38d
Aug 8, 2024 Quarterly ↗ Jun 30, 2024 39d
May 9, 2024 Quarterly ↗ Mar 31, 2024 39d
Feb 26, 2024 Annual ↗ Dec 31, 2023 57d
Nov 2, 2023 Quarterly ↗ Sep 30, 2023 33d

Current reports